Current research
This section provides you with the research base for the medical use of cannabis.
1. Studies in progress
2. Completed studies
https://www.leafly.com/news/health/medical-marijuana-research-studies-spring-2018
https://www.leafly.com/news/health/medical-marijuana-research-studies-summer-2018
Dronabinol (Marinol®) is FDA-approved for the treatment of anorexia/weight loss in AIDS and for nausea/emesis associated with chemotherapy, which is now being used off-label for Agit-AD. Dronabinol is a synthetic oral formulation of delta-9-tetrahydrocannabinol (THC), a psychoactive constituent of the cannabis plant that acts as a partial agonist at the Type 1 (CB1) and Type 2 (CB2) endocannabinoid receptors. This pharmacology is appropriate for targeting Agit-AD because CB1 receptor agonism can produce anxiolytic and antidepressant effects and CB2 receptor agonism can be anti-inflammatory.
I'm another title
I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. I’m a great place for you to tell a story and let your users know a little more about you.
Overall, our results suggest a statistically detectable but limited association between cannabis use and cognitive functioning in youth. These results were surprisingly similar to those from prior meta-analyses in adult samples. We found little evidence for more severe effects with cannabis use at earlier ages or specifically in adolescence.
I'm another title
I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. I’m a great place for you to tell a story and let your users know a little more about you.